National Cancer Institute

Last updated
National Cancer Institute (NCI)
National Cancer Institute logo.svg
Agency overview
FormedAugust 5, 1937;86 years ago (1937-08-05)
Jurisdiction Federal government of the United States
HeadquartersOffice of the Director,
31 Center Drive, Building 31, Bethesda, Maryland,
20814
Agency executive
Parent department United States Department of Health and Human Services
Parent agency National Institutes of Health
Child agencies
Website www.cancer.gov OOjs UI icon edit-ltr-progressive.svg
Footnotes
[1] [2] [3] [4] [5]

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

Contents

NCI is the oldest and has the largest budget and research program of the 27 institutes and centers of the NIH ($6.9 billion in 2020). [6] It fulfills the majority of its mission via an extramural program that provides grants for cancer research. Additionally, the National Cancer Institute has intramural research programs in Bethesda, Maryland, and at the Frederick National Laboratory for Cancer Research [7] at Fort Detrick in Frederick, Maryland. The NCI receives more than US$5 billion in funding each year. [8]

The NCI supports a nationwide network of 72 NCI-designated Cancer Centers with a dedicated focus on cancer research and treatment [9] and maintains the National Clinical Trials Network. [10]

History

Timeline

An early wooden sign for the National Cancer Institute Wooden sign.jpg
An early wooden sign for the National Cancer Institute
Members of the first National Advisory Cancer Council at the groundbreaking ceremonies of the NCI's building 6 in Bethesda, Maryland (June 1938) NIH building 6 groundbreaking.jpg
Members of the first National Advisory Cancer Council at the groundbreaking ceremonies of the NCI's building 6 in Bethesda, Maryland (June 1938)

Anti-cancer drug investigations

Organization

The NCI is divided into several divisions and centers. [18]

Intramural

The CCR includes approximately 250 internal NCI research groups in Frederick and Bethesda. [19]
DCEG is made up of eight branches within the Trans-divisional Research Program. [20]

Extramural

DCB oversees approximately 2000 grants per year in the areas of cancer cell biology; cancer immunology, hematology, and etiology; DNA and chromosome aberrations; structural biology and molecular applications; tumor biology and microenvironment; and tumor metastasis. [21] "Special Research Programs" falling under the aegis of the DCB include: Physical Sciences-Oncology Network, Cancer Systems Biology Consortium, Oncology Models Forum, Barrett's Esophagus Translational Research Network, New Approaches to Synthetic Lethality for Mutant KRAS-Dependent Cancers, Molecular and Cellular Characterization of Screen-Detected Lesions, Fusion Oncoproteins in Childhood Cancers, and Cancer Tissue Engineering Collaborative. [22]
DCTD supports eight research programs: The Biometric Research Program, The Cancer Diagnosis Program, The Cancer Imaging Program, The Cancer Therapy Evaluation Program, The Developmental Therapeutics Program, The Radiation Research Program, The Translational Research Program, and The Office of Cancer Complementary and Alternative Medicine. [23]
DEA processes and supports the thousands of grant applications NCI receives each year and compiles reports on the progress of research funded by the NCI's programs. [24]

Office of the director

CCG was created in 2011 and is responsible for management of The Cancer Genome Atlas and cancer genomics initiatives.
In the 1990s, the Unconventional Innovation Program was created to integrate interdisciplinary technology research with biological applications. It was reorganized in 2004 as the CSSI. [25]

Programs

NCI-designated Cancer Centers

The NCI-designated Cancer Centers are one of the primary arms in the NCI's mission in supporting cancer research. There are currently 72 so-designated centers; 9 cancer centers, 56 comprehensive cancer centers, and 7 basic laboratory cancer centers. NCI supports these centers with grant funding in the form of P30 Cancer Center Support Grants to support shared research resources and interdisciplinary programs. Additionally, faculty at the cancer centers receive approximately 75% of the grant funding awarded by the NCI to individual investigators. [9] [26]

The NCI cancer centers program was introduced in 1971 with 15 participating institutions. [27]

National Clinical Trials Network

The National Clinical Trials Network (NCTN) was formed in 2014, from the Cooperative Group program to modernize the existing system to support precision medicine clinical trials. With precision medicine, many patients must be screened to determine eligibility for treatments in development.[ citation needed ]

Lead Academic Participating Sites (LAPS) were chosen at 30 academic institutions for their ability to conduct clinical trials and screen a large number of participants and awarded grants to support the infrastructure and administration required for clinical trials. Most LAPS grant recipients are also NCI-designated cancer centers. [10] NCTN also stores surgical tissue from patients in a nationwide network of tissue banks at various universities. [28]

Developmental Therapeutics Program

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents. [29]

Under the label "Discovery & Development Services" several services are offered, among them the NCI-60 human cancer cell line screen and the Molecular Target Program. [30]

In the Molecular Target Program thousands of molecular targets have been measured in the NCI panel of 60 human tumor cell lines. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels. [31]

NCI-60 Human Tumor Cell Lines Screen

The evolution of strategies at the NCI illustrates the changes in screening that have resulted from advances in cancer biology. The Developmental Therapeutics Program (DTP) operates a tiered anti-cancer compound screening program with the goal of identifying novel chemical leads and biological mechanisms. The DTP screen is a three phase screen which includes: an initial screen which first involves a single dose cytotoxicity screen with the 60 cell line assay. Those passing certain thresholds are subjected to a 5 dose screen of the same 60 cell-line panel to determine a more detailed picture of the biological activity. A second phase screen establishes the maximum tolerable dosage and involves in vivo examination of tumor regression using the hollow fiber assay. The third phase of the study is the human tumor xenograft evaluation.

Active compounds are selected for testing based on several criteria: disease type specificity in the in vitro assay, unique structure, potency, and demonstration of a unique pattern of cellular cytotoxicity or cytostasis, indicating a unique mechanism of action or intracellular target.

A high correlation of cytotoxicity with compounds of known biological mechanism is often predictive of the drugs mechanism of action and thus a tool to aid in the drug development and testing. It also tells if there is any unique response of the drug which is not similar to any of the standard prototype compounds in the NCI database.

Leadership

PortraitDirectorTenureNotes
Portrait photo of Carl Voegtlin.jpg Carl Voegtlin [32] January 13, 1938 – July 31, 1943
Roscoe Roy Spencer.jpg Roscoe Roy Spencer August 1, 1943 – July 1, 1947
Rear Admiral Leonard Scheele.jpg Leonard Andrew Scheele July 1, 1947 – April 6, 1948Served as the seventh Surgeon General of the United States from 1948 to 1956.
John R. Heller.jpg John Roderick Heller May 15, 1948 – July 1, 1960
Former National Cancer Institute director Kenneth Endicott (1960-1969).jpg Kenneth Milo Endicott July 1, 1960 – November 10, 1969
Carl Gwin Baker.jpg Carl Gwin Baker July 13, 1970 – May 5, 1972
Frank Joseph Rauscher.jpg Frank Joseph Rauscher, Jr. May 5, 1972 – November 1, 1976
Former National Cancer Institute director Arthur Upton (1977 - 1979) (1).jpg Arthur Canfield Upton July 29, 1977 – December 31, 1980
Nci-vol-2727-300 Vincent DeVita.jpg Vincent T. DeVita, Jr. July 9, 1980 – September 1, 1988
Samuel Broder MD nci-vol-4344-300.jpg Samuel Broder December 22, 1988 – April 1, 1995
Richard D. Klausner 2002.jpg Richard D. Klausner August 1, 1995 – September 30, 200111th Director, left to become President of the Case Institute of Health, Science, and Technology and later Executive Director of Global Health for the Bill & Melinda Gates Foundation. [33]
AVonEchenbach2.jpg Andrew C. von Eschenbach January 22, 2002 – June 10, 200612th Director, served from 2001 to 2006 before transitioning to a role as Commissioner of Food and Drugs. [34] [35]
Jniederhuber-photo.jpg John E. Niederhuber September 15, 2006 – July 12, 201013th Director of the NCI, was nominated by President George W. Bush. [36]
National Cancer Institute director Harold E. Varmus (3) (cropped).jpg Harold Varmus July 12, 2010 – March 31, 2015Co-winner of the Nobel Prize for studies of the genetic basis of cancer. [37] He was director of the National Institutes of Health from 1993 to 1999.
Ned Sharpless official portrait.jpg Norman E. Sharpless October 17, 2017 – April 30, 202215th Director of the NCI. [38] [39] Transitioned to acting Commissioner of Food and Drugs in April 2019 and returned to NCI in November 2019. [40]
Monica M. Bertagnolli, NCI Director.png Monica Bertagnolli October 17, 2022 – November 9, 202316th Director of NCI. First woman to hold the position. [41]
Kimryn Rathmell December 18, 2023 – Present17th Director of NCI. [42]

Notable NCI faculty

Notable people

See also

Notes and references

  1. ↑ "Director's Page". National Cancer Institute. Retrieved 1 April 2015.
  2. ↑ "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI". National Cancer Institute. 18 December 2018. Retrieved 1 January 2019.
  3. ↑ "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)". NED.NIH.gov. Retrieved 2 January 2019.
  4. ↑ "Visitor Information". National Cancer Institute. 1980-01-01. Retrieved 2 January 2019.
  5. ↑ NCI's Shady Grove Campus To Open In 2013. Vol. LXII. 2 April 2010. Retrieved 2 January 2019. The change is being made primarily due to the leases expiring at EPN, EPS and a few other buildings on Executive Blvd. The new buildings would house, in one facility, staff from those leased sites... NCI will continue to occupy floors 10 and 11 of Bldg. 31's A wing, as well as much of the 3rd floor, and the NCI director will remain in 31. There are also many staff members in lab buildings and the Clinical Center on campus and a large presence in Frederick at Ft. Detrick.{{cite book}}: |work= ignored (help)
  6. ↑ Philippidis, Alex (2020-09-21). "Top 50 NIH-Funded Institutions of 2020". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-04-25.
  7. ↑ "NCI-Frederick: NCI-Frederick Home Page". NCIfCrf.gov. Archived from the original on 16 October 2012. Retrieved 18 December 2011.
  8. ↑ "Funding Trends". National Cancer Institute. 2018-12-20.
  9. 1 2 "NCI-Designated Cancer Centers". National Cancer Institute. 5 April 2012. Retrieved July 26, 2019.
  10. 1 2 "NCI's National Clinical Trials Network". National Cancer Institute. 2014-05-29.
  11. ↑ "National Cancer Institute Act: Text of the Act of August 5, 1937, creating the National Cancer Institute and authorizing an appropriation therefor". JNCI Journal of the National Cancer Institute. 19 (2): 133–137. 1 August 1957. doi:10.1093/jnci/19.2.133. ISSN   0027-8874. PMID   13502712.
  12. ↑ "Statutes at Large Volume 50 (1937) Table of Contents; VOL. 49 – VOL. 51". LegisWorks.org. Archived from the original on 6 March 2016. Retrieved 1 January 2019.
  13. ↑ "75th Congress Public Law 244" (PDF). LegisWorks.org. Archived from the original (PDF) on 7 March 2016. Retrieved 1 January 2019.
  14. ↑ "Statute 50 Page 559" (PDF). LegisWorks.org. Archived from the original (PDF) on 17 March 2016. Retrieved 1 January 2019.
  15. ↑ December 13, 2016—Important Events in NCI History—National Cancer Institute (NCI). 18 October 2017. Retrieved 1 January 2019.{{cite book}}: |work= ignored (help)
  16. ↑ Kaplan, Sheila (2019-03-12). "National Cancer Chief, Ned Sharpless, Named F.D.A.'s Acting Commissioner". The New York Times. ISSN   0362-4331 . Retrieved 2019-12-04.
  17. ↑ Collins, Francis (November 1, 2019). "Statement on the return of Dr. Ned Sharpless as NCI Director". The NIH Director. Retrieved December 3, 2019.
  18. ↑ "NCI Organization". National Cancer Institute. 1980-01-01.
  19. ↑ "About CCR". 21 July 2014.
  20. ↑ "DCEG Home". Division of Cancer Epidemiology and Genetics – National Cancer Institute. 1980-01-01.
  21. ↑ "DCB Research Portfolio". National Cancer Institute. 2016-08-08.
  22. ↑ "Division of Cancer Biology". National Cancer Institute. 2016-08-08.
  23. ↑ "About DCTD – DCTD". dctd.cancer.gov.
  24. ↑ "About NCI Division of Extramural Activities". deainfo.nci.nih.gov.
  25. ↑ "History – Center for Strategic Scientific Initiatives (CSSI)". cssi.cancer.gov. Archived from the original on 2017-09-29. Retrieved 2017-09-28.
  26. ↑ "OCC Homepage – OCCWebApp 2.1.0". cancercenters.cancer.gov.
  27. ↑ "History of the NCI Cancer Centers Program". National Cancer Institute. 2012-08-13.
  28. ↑ "NCTN Biospecimen Banks". nctnbanks.cancer.gov. Retrieved 2024-01-22.
  29. ↑ "Welcome to the Developmental Therapeutics Program". Developmental Therapeutics Program . National Cancer Institute. Retrieved 6 January 2018.
  30. ↑ "Discovery & Development Services". Developmental Therapeutics Program . National Cancer Institute. 26 August 2015. Retrieved 6 January 2018.
  31. ↑ "Molecular Targets". Developmental Therapeutics Program . National Cancer Institute. 12 May 2015. Retrieved 7 January 2018.
  32. ↑ "National Cancer Institute (NCI)". 7 July 2015.
  33. ↑ "Dr. Richard D. Klausner Named Executive Director of Global Health for Bill & Melinda Gates Foundation".
  34. ↑ U.S. Congress (7 December 2006). "Executive Session". Congressional Record. 152 (134): S11404–29, S11447–51. Retrieved 2006-12-12.
  35. ↑ "U.S. Senate: U.S. Senate Roll Call Votes 109th Congress – 2nd Session". www.senate.gov.
  36. ↑ "Emergent Biosolutions – Board of Directors bio" . Retrieved 2013-12-06.
  37. ↑ "Director's Page – National Cancer Institute (Archive)". Cancer.gov. Archived from the original on 2015-03-31. Retrieved 2015-04-02.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  38. ↑ "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI". National Cancer Institute. 18 December 2018. Retrieved 1 January 2019.[ verification needed ]
  39. ↑ "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)". NED.NIH.gov. Retrieved 2 January 2019.[ verification needed ]
  40. ↑ "NCI Director Dr. Norman E. Sharpless". National Cancer Institute. 2017-10-17. Retrieved 2020-02-12.
  41. ↑ "Monica Bertagnolli becomes NCI director - NCI". www.cancer.gov. 2022-10-03. Retrieved 2022-10-21.
  42. ↑ "W. Kimryn Rathmell begins work as 17th director of the National Cancer Institute". www.cancer.gov. 2023-12-18. Retrieved 2023-12-26.

General references

Related Research Articles

<span class="mw-page-title-main">National Institutes of Health</span> US government medical research agency

The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

The National Heart, Lung, and Blood Institute (NHLBI) is the third largest Institute of the National Institutes of Health, located in Bethesda, Maryland, United States. It is tasked with allocating about $3.6 billion in FY 2020 in tax revenue to advancing the understanding of the following issues: development and progression of disease, diagnosis of disease, treatment of disease, disease prevention, reduction of health care disparities within the American population, and advancing the effectiveness of the US medical system. NHLBI's Director is Gary H. Gibbons (2012–present).

The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.

<span class="mw-page-title-main">Cancer and Leukemia Group B</span> U.S. research cooperative group

Cancer and Leukemia Group B is a cancer research cooperative group in the United States.

<span class="mw-page-title-main">Sanford Burnham Prebys Medical Discovery Institute</span> Non-profit medical research institute

Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.

The "war on cancer" is the effort to find a cure for cancer by increased research to improve the understanding of cancer biology and the development of more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death. The signing of the National Cancer Act of 1971 by United States president Richard Nixon is generally viewed as the beginning of this effort, though it was not described as a "war" in the legislation itself.

<span class="mw-page-title-main">Yale Cancer Center</span> Hospital in Connecticut, United States

Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer". It is one of a network of 56 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Currently directed by Dr. Eric Winer, the Cancer Center brings together the resources of the Yale School of Medicine (YSM), Yale New Haven Hospital (YNHH), and the Yale School of Public Health (YSPH).

The Office of Cancer Complementary and Alternative Medicine (OCCAM) is an office of the National Cancer Institute (NCI) in the Division of Cancer Treatment and Diagnosis. OCCAM was founded in 1998 and is responsible for NCI's research agenda in pseudoscientific complementary and alternative medicine (CAM), as it relates to cancer prevention, diagnosis, treatment, and symptom management. The OCCAM differs from the National Center for Complementary and Integrative Health in that it is exclusively focused on cancer, while the NCCIH funds a much broader program of NIH research into CAM for all diseases and disorders. It last produced an annual report in 2011 and spent $105 million on CAM research in 2011.

<span class="mw-page-title-main">John E. Niederhuber</span>

John E. Niederhuber, MD was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.

The University of Wisconsin Carbone Cancer Center (UWCCC) is a comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute (NCI), the lead federal agency for cancer research. It is an integral part of both the University of Wisconsin (UW) and the University of Wisconsin Hospital and Clinics. It is located in Madison, Wisconsin.

The Cancer Trials Support Unit(CTSU) is a service of the National Cancer Institute (NCI) in the United States.

Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.

<span class="mw-page-title-main">UNC Lineberger Comprehensive Cancer Center</span> Hospital in North Carolina, United States

The UNC Lineberger Comprehensive Cancer Center is a cancer research and treatment center at the University of North Carolina at Chapel Hill. One of 52 National Cancer Institute-designated comprehensive cancer centers in the United States, its clinical base is the N.C. Cancer Hospital, part of the UNC Health Care system. UNC Lineberger is the only public NCI-designated comprehensive cancer center in the state of North Carolina. The current director is H. Shelton Earp III who succeeded current NCI director Norman Sharpless.

<span class="mw-page-title-main">Douglas R. Lowy</span>

Douglas R. Lowy is the current Principal Deputy Director of the U.S. National Cancer Institute (NCI) and Chief of the Laboratory of Cellular Oncology within the Center for Cancer Research at NCI. Lowy served as Acting Director of NCI between April 2015 and October 2017 following the resignation of Harold E. Varmus, M.D., and again between April and November 2019, while Director Norman Sharpless served as the Acting Commissioner of the U.S. Food and Drug Administration. He resumed the role of Acting Director on May 1, 2022, when Sharpless stepped down until October 3, 2022 when Monica Bertagnolli was appointed Director. He resumed the role again in November 2023 after Bertagnolli resigned to serve as director of the National Institutes of Health.

<span class="mw-page-title-main">Norman Sharpless</span> American cancer researcher (born 1966)

Norman Edward "Ned" Sharpless is the previous Director of the National Cancer Institute (NCI). Before that, Sharpless was Professor of Medicine and Genetics Chair, Director of University of North Carolina UNC Lineberger Comprehensive Cancer Center, Molecular Therapeutics, Wellcome Distinguished Professorship in Cancer Research.

The Mayo Clinic Cancer Center (MCCC) is a National Cancer Institute (NCI)-designated Cancer Center and a division of the Mayo Clinic. The MCCC has 3 locations in the United States: Phoenix, Arizona, Jacksonville, Florida, and Rochester, Minnesota.

<span class="mw-page-title-main">Richard Klausner</span> American scientist

Richard D. Klausner is an American scientist who served as the 11th director of the National Cancer Institute of the United States.

<span class="mw-page-title-main">Worta McCaskill-Stevens</span> American physician-scientist (1949–2023)

Worta J. McCaskill-Stevens was an American physician-scientist and medical oncologist specialized in cancer disparities research, management of comorbidities within clinical trials, and molecular research for cancer prevention interventions. She was chief of the community oncology and prevention trials research group at the National Cancer Institute.

<span class="mw-page-title-main">Bríd Ryan</span> Irish biomedical scientist

Bríd M. Ryan is an Irish biomedical scientist and cancer researcher. She was an investigator at the National Cancer Institute from 2013 to 2021.

<span class="mw-page-title-main">Brigitte C. Widemann</span> German-American pediatric oncologist

Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.